You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
Product Class Date Terms of Agreement<br />
TAK 599/PPI 0903 J 2003 Takeda out-licensed TAK 599 to Peninsula, for exclusive<br />
development worldwide, excluding Japan. Takeda will be<br />
responsible for manufacture, worldwide.<br />
LGD 2226 G 2001 Ligand granted TAP exclusive worldwide rights to<br />
manufacture and sell any products resulting from the<br />
companies’ collaboration in the field of selective androgen<br />
receptor modulators (SARMs), including LGD 2226, for<br />
the treatment of certain androgen-related diseases and<br />
disorders. In 2003, the companies announced plans to<br />
extend their research collaboration in this area for one<br />
year.<br />
Y 128 N 2001 Takeda gained exclusive worldwide development and<br />
marketing rights from Welfide (now Mitsubishi Pharma).<br />
lestaurtinib (CEP 701) L 1999 Licensed out to TAP from Cephalon for the USA.<br />
febuxostat (TMX 67) M 1999 Licensed in by TAP from Teijin for North America.<br />
asoprisnil G N/A Licensed-in by TAP from Jenapharma (now part of<br />
Schering AG).<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 98
Change language